Dual Targeting of Aurora Kinases With AMG 900 Exhibits Potent Preclinical Activity Against Acute Myeloid Leukemia With Distinct Post-Mitotic Outcomes

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0186
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Inhibition of Flt3 and Pim Kinases by Ec-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

A Novel Treatment Strategy Targeting Aurora Kinases in Acute Myelogenous Leukemia

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Optimizing Survival Outcomes With Post‐remission Therapy in Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

Pin1 Inhibition Exerts Potent Activity Against Acute Myeloid Leukemia Through Blocking Multiple Cancer-Driving Pathways

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2018English

Acute Myeloid Leukemia With T(10;11): A Pathological Entity With Distinct Clinical Presentation

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2015English

Treatment Patterns and Outcomes of Octogenarian Patients With Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

Cytogenetic Heterogeneity Negatively Impacts Outcomes in Patients With Acute Myeloid Leukemia

Haematologica
Hematology
2014English

A Novel, Dual Pan-Pim/Flt3 Inhibitor SEL24 Exhibits Broad Therapeutic Potential in Acute Myeloid Leukemia

Oncotarget
Oncology
2018English

Dual Roles of EZH2 in Acute Myeloid Leukemia

Journal of Experimental Medicine
MedicineAllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy